Lead Product(s) : Surufatinib,Camrelizumab
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : HengRui
Deal Size : Undisclosed
Deal Type : Collaboration
HUTCHMED Initiates Phase II/III Trial of Surufatinib & Camrelizumab for Pancreatic Cancer
Details : Hutchmed will initiate a clinical advancement of their lead product Sulanda (surufatinib) in combination with camrelizumab for the treatment of naïve pancreatic ductal adenocarcinoma.
Brand Name : Sulanda
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 15, 2024
Lead Product(s) : Surufatinib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : HengRui
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Safety and efficacy of HMPL-012 (surufatinib), an oral inhibitor of angiogenesis and immune modulation, was demonstrated in SANET-p and SANET-ep studies, in patients with advanced pNETs and epNETs conducted in China.
Brand Name : HMPL-012
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 02, 2022
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Surufatinib,Toripalimab,Etoposide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sulanda (Surufatinib), a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptors and fibroblast growth factor receptor.
Brand Name : Sulanda
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 10, 2021
Lead Product(s) : Surufatinib,Toripalimab,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Surufatinib,Toripalimab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SURTORI-01, a Phase III study to evaluate the efficacy and safety of surufatinib (SULANDA), a novel, oral angio-immuno kinase inhibitor in combination with toripalimab compared with FOLFIRI to treat patients with advanced neuroendocrine carcinoma.
Brand Name : Sulanda
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 21, 2021
Lead Product(s) : Surufatinib,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Surufatinib received fast track designation in April 2020 for the treatment of pancreatic and extra-pancreatic NET. Orphan Drug Designation for pancreatic NET was also granted in November 2019.
Brand Name : HMPL-012
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2021
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Surufatinib,Tislelizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This trial is to explore potential synergistic activity of the novel, oral angio-immuno kinase inhibitor surufatinib with the anti-PD-1 antibody tislelizumab in enhancing overall antitumor activity from inhibition of angiogenesis along with stimulation o...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 24, 2021
Lead Product(s) : Surufatinib,Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The NMPA approval of Sulanda® was based on results from the SANET-ep study. The Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS in all subgroups of non-pancreatic NET patients with an acceptab...
Brand Name : Sulanda
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 30, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio.
Brand Name : HMPL-012
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 28, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”).
Brand Name : HMPL-012
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 20, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
Details : The NDA is supported by data from the successful SANET-p study, a Phase III pivotal study of surufatinib in advanced neuroendocrine tumors – pancreatic patients in China for whom there is no effective therapy.
Brand Name : HMPL-012
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 17, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?